Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows PCT-guided therapy improves clinical outcomes in sepsis patients, suggesting effective management.
Background: Procalcitonin (PCT), a biomarker closely associated with bacterial infections, has emerged as a valuable tool in guiding antibiotic therapy. In sepsis management, it may help optimize antibiotic use and improve clinical outcomes. This retrospective cohort study aimed to evaluate the effectiveness of PCT-guided antibiotic therapy in adult sepsis patients, with a particular focus on biochemical responses. Methods: We retrospectively analyzed medical records of 110 adult sepsis patients admitted between January 2019 and December 2023. Patients were allocated to either a standard antibiotic group (n=53) or a PCT-guided antibiotic group (n=57). Key variables included demographic data, treatment duration, infection control metrics, and laboratory parameters such as white blood cell (WBC) count, C-reactive protein (CRP), and PCT levels before and after therapy. Results: Compared to the standard group, the PCT-guided group exhibited significantly greater reductions in WBC, CRP, and PCT levels (P < 0.05), shorter antibiotic duration, fewer secondary infections, and improved antibiotic de-escalation rates. A higher complete response rate (17.54% vs. 3.77%) was also observed in the PCT-guided group. No significant difference was found in 28-day mortality. Conclusions: PCT-guided antibiotic therapy led to more favorable changes in key biochemical markers and clinical outcomes, supporting its role as a biomarker-driven approach to antibiotic optimization in sepsis management.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: